Comparative Effectiveness of Several Second-Line Dual Oral Antidiabetic Combinations in Reducing Cardiovascular Events in Type 2 Diabetes-A Nationwide Study

被引：0
|
作者：
Chang, Chia-Hsuin
Chang, Yi-Cheng
Lin, Jou-Wei
Chen, Shu-Ting
Lai, Mei-Shu
Chuang, Lee-Ming
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2408-PO
引用
收藏
页码：A611 / A611
页数：1
相关论文
共 50 条
  • [41] Effectiveness of Second-Line Agents in the Treatment of Uncomplicated Type 2 Diabetes Mellitus: An Observational Tertiary-Care Based Study
    Gill, Rupam
    Adiga, Shalini
    Varma, Muralidhar
    JOURNAL OF YOUNG PHARMACISTS, 2018, 10 (03) : 334 - 339
  • [42] Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
    Douros, Antonios
    Dell'Aniello, Sophie
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    Azoulay, Laurent
    Suissa, Samy
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [43] Durability of Second-Line Oral Glucose-Lowering Therapy in Type 2 Diabetes: Results of a Large UK Cohort Study
    Mamza, Jil
    Mehta, Raj
    Donnelly, Richard
    Idris, Iskandar
    DIABETES, 2015, 64 : A39 - A39
  • [44] Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records
    Zghebi, S. S.
    Steinke, D. T.
    Rutter, M. K.
    Emsley, R. A.
    Ashcroft, D. M.
    DIABETES OBESITY & METABOLISM, 2016, 18 (09): : 916 - 924
  • [45] Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes
    Zaccardi, Francesco
    Jacquot, Emmanuelle
    Cortese, Viviana
    Tyrer, Freya
    Seidu, Samuel
    Davies, Melanie J.
    Khunti, Kamlesh
    DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2417 - 2426
  • [46] Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease
    Deng, Yu
    Ghamsari, Farhad
    Lu, Alice
    Yu, Jingzhi
    Zhao, Lihui
    Kho, Abel N.
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2022, 30
  • [47] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE AND THIRD-LINE ANTIDIABETIC DRUGS IN TYEP 2 DIABETES: AN EMPIRICAL, POPULATION-BASED OBSERVATIONAL STUDY FROM TAIWAN
    Ou, H. T.
    Balkrishnan, R.
    Yang, C. Y.
    Chang, K. C.
    VALUE IN HEALTH, 2015, 18 (03) : A61 - A62
  • [48] Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study
    Gottlieb, Assaf
    Yanover, Chen
    Cahan, Amos
    Goldschmidt, Yaara
    BMJ OPEN DIABETES RESEARCH & CARE, 2017, 5 (01)
  • [49] Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes
    Ou, Huang-Tz
    Chang, Kai-Cheng
    Li, Chung-Yi
    Wu, Jin-Shang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (07) : 1556 - 1570
  • [50] Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)
    Mathieu, C.
    Barnett, A. H.
    Brath, H.
    Conget, I.
    de Castro, J. J.
    Goeke, R.
    Marquez Rodriguez, E.
    Nilsson, P. M.
    Pagkalos, E.
    Penfornis, A.
    Schaper, N. C.
    Wangnoo, S. K.
    Kothny, W.
    Bader, G.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (10) : 947 - 956
12345